Clinical Trial Update: FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating FOLFOX-HAIC combined with donafenib and pucotenlimab as first-line treatment for unresectable intrahepatic cholangiocarcinoma.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Donafenib (donafenib)
• FOLFOX-HAIC
• Pucotenlimab

Snippet

Sponsor: Sun Yat-sen University | Conditions: Intrahepatic Cholangiocarcinoma (Icc), Hepatic Arterial Infusion Chemotherapy | Phase 2 | Status: NOT_YET_RECRUITING